v3.26.3
Additional Information to the Items of Profit or Loss
 6 Months Ended
Jun. 30, 2026
Additional Information to the Items of Profit or Loss [Abstract]  
ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS

NOTE 12:- ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS

 

   

Six months ended

June 30,

  
    2026     2025  
    Unaudited  
    USD in thousands  
a. Research and development expenses:            
             
Wages and related expenses   $ 424     $ 154  
Share-based payment     204       42  
Clinical studies     325       181  
Regulatory, professional and other expenses     367       390  
Research and preclinical studies     184       129  
Chemistry and formulations     71       42  
                 
      1,575       938  
                 
b. General and administrative expenses:                
                 
Wages and related expenses     450       226  
Share-based payment     995       224  
Professional and directors’ fees     1,353       1,368  
Business development expenses     135       48  
Deemed issuance listing expenses     -       -  
Office maintenance, rent and other expenses     67       78  
Investor relations and business expenses     68       54  
Regulatory expenses     130       111  
                 
    $ 3,198     $ 2,109